Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for vTv Therapeutics (VTVT) over the last 11 years, with Q3 2025 value amounting to $1.0 million.

  • vTv Therapeutics' Share-based Compensation rose 1805.39% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 5310.49%. This contributed to the annual value of $2.8 million for FY2024, which is 7471.48% up from last year.
  • According to the latest figures from Q3 2025, vTv Therapeutics' Share-based Compensation is $1.0 million, which was up 1805.39% from $930000.0 recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Share-based Compensation registered a high of $1.0 million during Q3 2025, and its lowest value of $167000.0 during Q2 2022.
  • Over the past 5 years, vTv Therapeutics' median Share-based Compensation value was $452000.0 (recorded in 2021), while the average stood at $563842.1.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 7072.43% in 2022, then soared by 26954.55% in 2025.
  • Over the past 5 years, vTv Therapeutics' Share-based Compensation (Quarter) stood at $994000.0 in 2021, then crashed by 70.72% to $291000.0 in 2022, then skyrocketed by 38.49% to $403000.0 in 2023, then skyrocketed by 104.71% to $825000.0 in 2024, then rose by 22.06% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $930000.0 for Q2 2025, and $813000.0 during Q1 2025.